Serdexmethylphenidate
Serdexmethylphenidate is a prodrug of d-methylphenidate designed to provide an extended-duration, abuse-deterrent formulation for the treatment of attention deficit hyperactivity disorder (ADHD). The prodrug is cleaved by gut enzymes to release d-methylphenidate, which inhibits dopamine and norepinephrine reuptake transporters in the prefrontal cortex and striatum, enhancing executive function and attention. The prodrug design confers reduced abuse potential because parenteral administration does not provide rapid dopamine surge.
Masse moléculaire
499,5000 g/mol
LogP
2,20
TPSA
149,00 Ų
Règle des 5 de Lipinski
Conforme
Mécanisme d'action
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Structure 2D
Cite this structure
Embed this structure
SMILES
COC(=O)[C@H](c1ccccc1)[C@H]1CCCCN1C(=O)OC[n+]1cccc(C(=O)N[C@@H](CO)C(=O)O)c1
InChI
InChI=1S/C25H29N3O8/c1-35-24(33)21(17-8-3-2-4-9-17)20-11-5-6-13-28(20)25(34)36-16-27-12-7-10-18(14-27)22(30)26-19(15-29)23(31)32/h2-4,7-10,12,14,19-21,29H,5-6,11,13,15-16H2,1H3,(H-,26,30,31,32)/p+1/t19-,20+,21+/m0/s1
Molecular Formula
C25H29N3O8
HBD / HBA
2 / 8
Liaisons Rotatives
10
Atomes Lourds
36
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Foire aux questions
Serdexmethylphenidate is a prodrug of d-methylphenidate designed to provide an extended-duration, abuse-deterrent formulation for the treatment of attention deficit hyperactivity disorder (ADHD). The prodrug is cleaved by gut enzymes to release d-methylphenidate, which inhibits dopamine and norepinephrine reuptake transporters in the prefrontal cortex and striatum, enhancing executive function and attention. The prodrug design confers reduced abuse potential because parenteral administration does not provide rapid dopamine surge.
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Yes, Serdexmethylphenidate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4301162. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 134823895. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="serdexmethylphenidate"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/serdexmethylphenidate/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/serdexmethylphenidate/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/serdexmethylphenidate/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="serdexmethylphenidate"></drugfyi-drug>